38.15 USD
+1.02 (+2.75%)
Taking everything into account, IBEX scores 7 out of 10 in our fundamental rating. IBEX was compared to 85 industry peers in the IT Services industry. IBEX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IBEX is growing strongly while it also seems undervalued. This is an interesting combination This makes IBEX very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year IBEX was profitable.
IBEX had a positive operating cash flow in the past year.
IBEX had positive earnings in each of the past 5 years.
IBEX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IBEX (14.58%) is better than 92.94% of its industry peers.
With an excellent Return On Equity value of 28.81%, IBEX belongs to the best of the industry, outperforming 91.76% of the companies in the same industry.
IBEX's Return On Invested Capital of 21.63% is amongst the best of the industry. IBEX outperforms 94.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.58% | ||
| ROE | 28.81% | ||
| ROIC | 21.63% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 7.14%, IBEX is in the better half of the industry, outperforming 72.94% of the companies in the same industry.
IBEX's Profit Margin has improved in the last couple of years.
IBEX has a Operating Margin of 9.18%. This is in the better half of the industry: IBEX outperforms 67.06% of its industry peers.
IBEX's Operating Margin has improved in the last couple of years.
IBEX has a Gross Margin (30.62%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of IBEX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.18% | ||
| PM (TTM) | 7.14% | ||
| GM | 30.62% |
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
IBEX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
IBEX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IBEX has an Altman-Z score of 5.28. This indicates that IBEX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.28, IBEX is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
IBEX has a debt to FCF ratio of 0.05. This is a very positive value and a sign of high solvency as it would only need 0.05 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.05, IBEX belongs to the best of the industry, outperforming 92.94% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that IBEX is not too dependend on debt financing.
IBEX's Debt to Equity ratio of 0.01 is amongst the best of the industry. IBEX outperforms 82.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.05 | ||
| Altman-Z | 5.28 |
ROIC/WACC2.4
WACC9.02%
2.3 Liquidity
A Current Ratio of 1.82 indicates that IBEX should not have too much problems paying its short term obligations.
IBEX has a Current ratio (1.82) which is in line with its industry peers.
A Quick Ratio of 1.82 indicates that IBEX should not have too much problems paying its short term obligations.
IBEX has a Quick ratio (1.82) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 41.96% over the past year.
Measured over the past years, IBEX shows a very strong growth in Earnings Per Share. The EPS has been growing by 41.04% on average per year.
The Revenue has grown by 12.86% in the past year. This is quite good.
IBEX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.62% yearly.
EPS 1Y (TTM)41.96%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%73.08%
Revenue 1Y (TTM)12.86%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.55%
3.2 Future
Based on estimates for the next years, IBEX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.72% on average per year.
Based on estimates for the next years, IBEX will show a quite strong growth in Revenue. The Revenue will grow by 9.19% on average per year.
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.81%
Revenue Next 2Y9.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.00, the valuation of IBEX can be described as very reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of IBEX indicates a rather cheap valuation: IBEX is cheaper than 87.06% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of IBEX to the average of the S&P500 Index (26.76), we can say IBEX is valued rather cheaply.
A Price/Forward Earnings ratio of 10.54 indicates a reasonable valuation of IBEX.
Based on the Price/Forward Earnings ratio, IBEX is valued cheaply inside the industry as 89.41% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of IBEX to the average of the S&P500 Index (23.96), we can say IBEX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12 | ||
| Fwd PE | 10.54 |
4.2 Price Multiples
89.41% of the companies in the same industry are more expensive than IBEX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, IBEX is valued a bit cheaper than the industry average as 68.24% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.47 | ||
| EV/EBITDA | 6.8 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IBEX has a very decent profitability rating, which may justify a higher PE ratio.
IBEX's earnings are expected to grow with 13.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.52
PEG (5Y)0.29
EPS Next 2Y13.72%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for IBEX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:IBEX (12/12/2025, 12:00:05 PM)
38.15
+1.02 (+2.75%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)
Earnings (Next)
Inst Owners94.03%
Inst Owner Change-3.84%
Ins Owners2.88%
Ins Owner Change-3.25%
Market Cap513.88M
Revenue(TTM)579.74M
Net Income(TTM)41.38M
Analysts45.71
Price Target39.78 (4.27%)
Short Float %1.11%
Short Ratio1.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.95%
Min EPS beat(2)20.05%
Max EPS beat(2)21.85%
EPS beat(4)4
Avg EPS beat(4)16.83%
Min EPS beat(4)10.89%
Max EPS beat(4)21.85%
EPS beat(8)7
Avg EPS beat(8)12.58%
EPS beat(12)10
Avg EPS beat(12)14.59%
EPS beat(16)12
Avg EPS beat(16)13.3%
Revenue beat(2)2
Avg Revenue beat(2)5.51%
Min Revenue beat(2)2.5%
Max Revenue beat(2)8.52%
Revenue beat(4)4
Avg Revenue beat(4)4.65%
Min Revenue beat(4)2.45%
Max Revenue beat(4)8.52%
Revenue beat(8)5
Avg Revenue beat(8)1.79%
Revenue beat(12)5
Avg Revenue beat(12)-0.35%
Revenue beat(16)7
Avg Revenue beat(16)-0.06%
PT rev (1m)1.3%
PT rev (3m)27.87%
EPS NQ rev (1m)-2.48%
EPS NQ rev (3m)1.29%
EPS NY rev (1m)5.47%
EPS NY rev (3m)10.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.79%
Revenue NY rev (1m)1.82%
Revenue NY rev (3m)6.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12 | ||
| Fwd PE | 10.54 | ||
| P/S | 0.89 | ||
| P/FCF | 16.47 | ||
| P/OCF | 9.59 | ||
| P/B | 3.58 | ||
| P/tB | 3.9 | ||
| EV/EBITDA | 6.8 |
EPS(TTM)3.18
EY8.34%
EPS(NY)3.62
Fwd EY9.49%
FCF(TTM)2.32
FCFY6.07%
OCF(TTM)3.98
OCFY10.43%
SpS43.04
BVpS10.66
TBVpS9.78
PEG (NY)0.52
PEG (5Y)0.29
Graham Number27.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.58% | ||
| ROE | 28.81% | ||
| ROCE | 26.64% | ||
| ROIC | 21.63% | ||
| ROICexc | 24.4% | ||
| ROICexgc | 26.15% | ||
| OM | 9.18% | ||
| PM (TTM) | 7.14% | ||
| GM | 30.62% | ||
| FCFM | 5.38% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.05 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 129.83% | ||
| Cap/Sales | 3.86% | ||
| Interest Coverage | 31.53 | ||
| Cash Conversion | 76.01% | ||
| Profit Quality | 75.39% | ||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z | 5.28 |
F-Score8
WACC9.02%
ROIC/WACC2.4
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.96%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%73.08%
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.86%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.55%
Revenue Next Year12.81%
Revenue Next 2Y9.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.48%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year68.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.26%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y19.11%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%
IBEX LTD / IBEX FAQ
Can you provide the ChartMill fundamental rating for IBEX LTD?
ChartMill assigns a fundamental rating of 7 / 10 to IBEX.
Can you provide the valuation status for IBEX LTD?
ChartMill assigns a valuation rating of 8 / 10 to IBEX LTD (IBEX). This can be considered as Undervalued.
What is the profitability of IBEX stock?
IBEX LTD (IBEX) has a profitability rating of 7 / 10.
Can you provide the financial health for IBEX stock?
The financial health rating of IBEX LTD (IBEX) is 7 / 10.
Can you provide the expected EPS growth for IBEX stock?
The Earnings per Share (EPS) of IBEX LTD (IBEX) is expected to grow by 22.95% in the next year.